The Cigna GroupMEX:CI +0.20%70 Altman Z2-Score is 1.47 as of Jun. 26, 2026, which is 29% above its 10-year median of 1.14. GuruFocus rates MEX:CI with a GF Score™ of 70/100 and a GF Value™ of MXN7,459.30 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 15 Healthcare Plans companies, The Cigna Group ranks worse than 53.33% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
The Cigna Group has a Altman Z2-Score of 1.47, indicating it is in Grey Zones. This implies that The Cigna Group is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for The Cigna Group's Altman Z2-Score or its related term are showing as below:
MEX:CI'
s Altman Z2-Score Range Over the Past 10 Years
Min: 0.04 Med: 1.14 Max: 3.74
Current: 1.46
During the past 13 years, The Cigna Group's highest Altman Z2-Score was 3.74. The lowest was 0.04. And the median was 1.14.
The Cigna Group (MEX:CI) Altman Z2-Score Explanation
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
The Cigna Group Altman Z2-Score Related Terms
The Cigna Group Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for The Cigna Group's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:CI vs ELV, HUM, CVS: Altman Z2-Score Comparison
For the Healthcare Plans subindustry, The Cigna Group's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Cigna Group Altman Z2-Score vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, The Cigna Group's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where The Cigna Group's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
The Cigna Group's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
-0.0625
+
3.26
*
0.3204
+
6.72
*
0.0649
+
1.05
*
0.3809
=
1.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
The Cigna Group (MEX:CI) has a Altman Z2-Score of 1.47 as of Jun. 26, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on The Cigna Group and its competitors. This is 29% above median its historical median of 1.14. Over the past decade, The Cigna Group's Altman Z2-Score has ranged from 0.04 to 3.74. According to the industry distribution chart, The Cigna Group ranks #8 out of 15 companies in the Healthcare Plans industry, placing it in the top 53.3%.
Is The Cigna Group's Altman Z2-Score too high?
The Cigna Group's current Altman Z2-Score of 1.47 is 29% above median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 3.74. The Healthcare Plans industry median Altman Z2-Score is 1.46. The Cigna Group's value of 1.47 is 0.7% above this industry median. Based on the distribution chart, The Cigna Group ranks #8 out of 15 companies in the Healthcare Plans industry, which is below the industry midpoint. Overall, The Cigna Group has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Cigna Group's Altman Z2-Score compare to ELV and HUM?
According to the Healthcare Plans industry distribution chart, The Cigna Group ranks #8 out of 15 companies for Altman Z2-Score. This places The Cigna Group in the lower half of its industry. The industry median Altman Z2-Score is 1.46. The Cigna Group's value of 1.47 is 0.7% above this benchmark. Historically, The Cigna Group's own Altman Z2-Score has ranged from 0.04 to 3.74 over the past decade. While the company's 10-year median is 1.14 vs. the industry median of 1.46, The Cigna Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Healthcare Plans company?
The median Altman Z2-Score among Healthcare Plans companies is 1.46, based on 15 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Cigna Group's current Altman Z2-Score of 1.47 is 0.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on The Cigna Group and its competitors. For the Healthcare Plans industry, the median Altman Z2-Score is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Cigna Group's current Altman Z2-Score is 1.47, which is 29% above median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Cigna Group stock overvalued right now?
Based on GuruFocus' analysis, The Cigna Group (MEX:CI) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN7,459.30, compared to a current price of MXN4,974.06 — trading 33.3% below its estimated fair value. The current Altman Z2-Score is 1.47, which is 29% above median its 10-year median of 1.14 and 0.7% above the Healthcare Plans industry median of 1.46. The Cigna Group's overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For The Cigna Group (MEX:CI), the current Altman Z2-Score is 1.47 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Cigna Group (MEX:CI) Overvalued in 2026?
Based on GuruFocus' analysis, The Cigna Group stock appears to be undervalued.
The current stock price of MXN4,974.06 is trading 33.3% below its estimated GF Value™ of MXN7,459.30.
GuruFocus considers The Cigna Group to be Significantly Undervalued.
Key valuation signals for MEX:CI:
Altman Z2-Score: 1.47 (29% above median its 10-year median of 1.14)
GF Value™: MXN7,459.30 vs. price of MXN4,974.06 (33.3% below fair value)
Industry Position: 0.7% above the Healthcare Plans median (#8 of 15)
No single metric tells the full story. See the MEX:CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.
70GF Score
Get the complete analysis for MEX:CI
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:CI has been successfully added to your 
